Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 1 (2004), Issue 5 (December)

1. BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study.
   Eur J Cancer, 40(18): 2788-93. [Abstract] [Full-text]
2. Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform.
   Cancer Genet Cytogenet, 155(2): 97-107. [Abstract] [Full-text]
3. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer.
   Int J Gynecol Cancer, 14(6): 1086-96. [Abstract] [Full-text]
4. HER-2 and cancer antigen 125 evaluation in ovarian borderline tumors by immunohistochemistry and fluorescence in situ hybridization.
   Int J Gynecol Cancer, 14(6): 1078-85. [Abstract] [Full-text]
5. Discordance between beliefs and recommendations of gynecologic oncologists in ovarian cancer management.
   Int J Gynecol Cancer, 14(6): 1055-62. [Abstract] [Full-text]
6. Survivin deregulation in beta-tubulin mutant ovarian cancer cells underlies their compromised mitotic response to taxol.
   Cancer Res, 64(23): 8708-14. [Abstract] [Full-text]
7. c-KIT codon 816 mutation in a recurrent and metastatic dysgerminoma of a 14-year-old girl: case study.
   Virchows Arch, 445(6): 651-4. [Abstract] [Full-text]
8. A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk.
   J Clin Endocrinol Metab, 89(12): 6340-7. [Abstract] [Full-text]
9. Non-Hodgkin malignant lymphoma revealed by an ovarian tumor case report and review of the literature.
   Gynecol Oncol, 95(3): 750-4. [Abstract] [Full-text]
10. Recurrent immature teratoma of the ovary: a case report of radical secondary cytoreduction with replacement of the aortic bifurcation.
    Gynecol Oncol, 95(3): 746-9. [Abstract] [Full-text]
11. Management of upper gastrointestinal obstruction in advanced ovarian cancer with intraluminal stents.
    Gynecol Oncol, 95(3): 739-41. [Abstract] [Full-text]
12. Bilateral primary ovarian leiomyoma in a young woman: case report and literature review.
    Gynecol Oncol, 95(3): 733-5. [Abstract] [Full-text]
13. Small cell carcinoma of the ovary with hypercalcemia causes severe pancreatitis and altered mental status.
    Gynecol Oncol, 95(3): 716-8. [Abstract] [Full-text]
14. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study.
    Gynecol Oncol, 95(3): 695-700. [Abstract] [Full-text]
15. Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer.
    Gynecol Oncol, 95(3): 686-90. [Abstract] [Full-text]
16. Polymorphisms of interleukin (IL)-1alpha, IL-1beta, IL-6, IL-10, and IL-18 and the risk of ovarian cancer.
    Gynecol Oncol, 95(3): 672-9. [Abstract] [Full-text]
17. A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer.
    Gynecol Oncol, 95(3): 624-31. [Abstract] [Full-text]
18. Expression status and mutational analysis of the ras and B-raf genes in ovarian granulosa cell and epithelial tumors.
    Gynecol Oncol, 95(3): 603-9. [Abstract] [Full-text]
19. Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms.
    Gynecol Oncol, 95(3): 570-5. [Abstract] [Full-text]
20. Retrospective analysis of weekly topotecan as salvage therapy in relapsed ovarian cancer.
    Gynecol Oncol, 95(3): 564-9. [Abstract] [Full-text]
21. Response of combination platinum and gemcitabine chemotherapy for recurrent epithelial ovarian carcinoma.
    Gynecol Oncol, 95(3): 539-45. [Abstract] [Full-text]
22. Ovarian tumor expression of an oviductal protein in the hen: a model for human serous ovarian adenocarcinoma.
    Gynecol Oncol, 95(3): 530-3. [Abstract] [Full-text]
23. The use of colorectal stents for palliation of large-bowel obstruction due to recurrent gynecologic cancer.
    Gynecol Oncol, 95(3): 513-7. [Abstract] [Full-text]
24. Phase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group study.
    Gynecol Oncol, 95(3): 506-12. [Abstract] [Full-text]
25. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group.
    Gynecol Oncol, 95(3): 496-9. [Abstract] [Full-text]
26. Upregulation of FasL by LPA on ovarian cancer cell surface leads to apoptosis of activated lymphocytes.
    Gynecol Oncol, 95(3): 488-95. [Abstract] [Full-text]
27. Predictors of final histology in patients with endometrial cancer.
    Gynecol Oncol, 95(3): 463-8. [Abstract] [Full-text]
28. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.
    Gynecol Oncol, 95(3): 449-55. [Abstract] [Full-text]
29. Correlation of tumor- and stromal-derived MT1-MMP expression with progression of human ovarian tumors in SCID mice.
    Gynecol Oncol, 95(3): 437-48. [Abstract] [Full-text]
30. No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers.
    Gynecol Oncol, 95(3): 430-6. [Abstract] [Full-text]
31. pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol.
    Clin Cancer Res, 10(23): 8085-93. [Abstract] [Full-text]
32. Pharmacokinetic model-predicted anticancer drug concentrations in human tumors.
    Clin Cancer Res, 10(23): 8048-58. [Abstract] [Full-text]
33. Care of elderly women with ovarian cancer.
    Geriatr Nurs, 25(6): 329-35. [Abstract] [Full-text]
34. Secondary surgical cytoreduction for advanced ovarian carcinoma.
    N Engl J Med, 351(24): 2489-97. [Abstract] [Full-text]
35. The use of models in "target" theory to evaluate the survival curves of human ovarian carcinoma cell line exposure to adriamycin combined with ultrasound.
    Ultrason Sonochem, 12(5): 345-8. [Abstract] [Full-text]
36. Monitoring of integrin-mediated adhesion of human ovarian cancer cells to model protein surfaces by quartz crystal resonators: evaluation in the impedance analysis mode.
    Biosens Bioelectron, 20(7): 1333-40. [Abstract] [Full-text]
37. Monosomy 22 as a diagnostic aid in a case of late recurrence of adult granulosa cell tumor of the ovary.
    Cancer Genet Cytogenet, 156(1): 83-5. [Abstract] [Full-text]
38. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis.
    Cancer, 101(12): 2760-70. [Abstract] [Full-text]
39. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase.
    J Biol Chem, 279(51): 53213-21. [Abstract] [Full-text]
40. Association of 20q13.2 copy number changes with the advanced stage of ovarian cancer-tissue microarray analysis.
    Eur J Obstet Gynecol Reprod Biol, 118(1): 81-5. [Abstract] [Full-text]
41. Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer.
    J Pathol, 205(1): 21-8. [Abstract] [Full-text]
42. Analysis of ovarian cancer cell lines using array-based comparative genomic hybridization.
    J Pathol, 205(1): 29-40. [Abstract] [Full-text]
43. Detection of epithelial ovarian cancer using 1H-NMR-based metabonomics.
    Int J Cancer, 113(5): 782-8. [Abstract] [Full-text]
44. Centrosome abnormalities in ovarian cancer.
    Int J Cancer, 113(5): 746-51. [Abstract] [Full-text]
45. Id-I stimulates cell proliferation through activation of EGFR in ovarian cancer cells.
    Br J Cancer, 91(12): 2042-7. [Abstract] [Full-text]
46. Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?
    Ann Oncol, 16(1): 47-50. [Abstract] [Full-text]
47. Pathophysiological dynamics of human ovarian surface epithelial cells in epithelial ovarian carcinogenesis.
    Int Rev Cytol, 242: 1-54. [Abstract] [Full-text]
48. Serous psammocarcinoma of the ovary: a case report and review of literature.
    Gynecol Oncol, 96(1): 259-62. [Abstract] [Full-text]
49. Familial female and male germ cell cancer. A new syndrome?
    Gynecol Oncol, 96(1): 254-5. [Abstract] [Full-text]
50. Laparoscopic resection of occult metastasis using the combination of FDG-positron emission tomography/computed tomography image fusion with intraoperative probe guidance in a woman with recurrent ovarian cancer.
    Gynecol Oncol, 96(1): 241-4. [Abstract] [Full-text]
51. Long natural history of recurrent granulosa cell tumor of the ovary 23 years after initial diagnosis: a case report and review of the literature.
    Gynecol Oncol, 96(1): 235-40. [Abstract] [Full-text]
52. Recurrent small cell lung cancer presenting as bilateral adnexal masses.
    Gynecol Oncol, 96(1): 232-4. [Abstract] [Full-text]
53. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
    Gynecol Oncol, 96(1): 222-6. [Abstract] [Full-text]
54. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary--a multivariate analysis.
    Gynecol Oncol, 96(1): 204-9. [Abstract] [Full-text]
55. CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma.
    Gynecol Oncol, 96(1): 143-9. [Abstract] [Full-text]
56. Clinicopathological features of ovarian carcinosarcomas: a single institution experience.
    Gynecol Oncol, 96(1): 136-42. [Abstract] [Full-text]
57. Experience with single-agent paclitaxel consolidation following primary chemotherapy with carboplatin, paclitaxel, and gemcitabine in advanced ovarian cancer.
    Gynecol Oncol, 96(1): 132-5. [Abstract] [Full-text]
58. Clinical applications of microarray technology: creatine kinase B is an up-regulated gene in epithelial ovarian cancer and shows promise as a serum marker.
    Gynecol Oncol, 96(1): 77-83. [Abstract] [Full-text]
59. The utility of hand-assisted laparoscopy in ovarian cancer.
    Gynecol Oncol, 96(1): 72-6. [Abstract] [Full-text]
60. Phase II evaluation of 9-aminocamptothecin (9-AC, NSC #603071) in platinum-resistant ovarian and primary peritoneal carcinoma: a Gynecologic Oncology Group Study.
    Gynecol Oncol, 96(1): 67-71. [Abstract] [Full-text]
61. Establishment of subrenal capsule xenografts of primary human ovarian tumors in SCID mice: potential models.
    Gynecol Oncol, 96(1): 48-55. [Abstract] [Full-text]
62. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma.
    Gynecol Oncol, 96(1): 42-7. [Abstract] [Full-text]
63. Role of pegylated liposomal doxorubicin in ovarian cancer.
    Gynecol Oncol, 96(1): 10-8. [Abstract] [Full-text]
64. Diagnostic accuracy of frozen section diagnosis of the adnexal mass: a metaanalysis.
    Gynecol Oncol, 96(1): 1-9. [Abstract] [Full-text]
65. Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma.
    Br J Cancer, 91(12): 2048-55. [Abstract] [Full-text]
66. Pediatric ovarian tumors: a review of 67 cases.
    Pediatr Blood Cancer, 44(2): 167-73. [Abstract] [Full-text]
67. Adeno-associated virus-mediated delivery of a mutant endostatin suppresses ovarian carcinoma growth in mice.
    Gene Ther, 12(1): 30-8. [Abstract] [Full-text]
68. Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus.
    Gene Ther, 12(1): 87-94. [Abstract] [Full-text]
69. Antiangiogenic cancer gene therapy by adeno-associated virus 2-mediated stable expression of the soluble FMS-like tyrosine kinase-1 receptor.
    Cancer Gene Ther, 12(1): 26-34. [Abstract] [Full-text]
70. Primary ovarian trabecular carcinoid tumour: a case report with an immunohistochemical study and a review of the literature.
    Arch Gynecol Obstet, 270(4): 274-7. [Abstract] [Full-text]
71. Ovarian metastases caused by cholangiocarcinoma: a rare Krukenberg's tumour simulating a primary neoplasm of the ovary: a two-case study.
    Arch Gynecol Obstet, 270(4): 281-4. [Abstract] [Full-text]
72. A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma.
    Cancer Res, 64(24): 8846-53. [Abstract] [Full-text]
73. Chronic appendicitis diagnosed preoperatively as an ovarian dermoid.
    J Pediatr Adolesc Gynecol, 17(6): 403-6. [Abstract] [Full-text]
74. Lower expression of cyclooxygenase-2: is it associated with the development of borderline ovarian tumors?
    Med Hypotheses, 64(2): 273-8. [Abstract] [Full-text]
75. Is semen an etiologic factor in the development of primary peritoneal carcinoma and epithelial ovarian cancer?
    Med Hypotheses, 64(2): 264-6. [Abstract] [Full-text]
76. CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin.
    Mol Cancer, 3: 33. [Abstract] [Full-text]
77. Up-regulation of interleukin-6 in human ovarian cancer cell via a Gi/PI3K-Akt/NF-kappaB pathway by lysophosphatidic acid, an ovarian cancer-activating factor.
    Carcinogenesis, 26(1): 45-52. [Abstract] [Full-text]
78. Poorer survival of elderly patients with ovarian cancer: a population-based study.
    Surg Oncol, 13(4): 181-6. [Abstract] [Full-text]
79. ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion.
    Int J Biochem Cell Biol, 37(3): 590-603. [Abstract] [Full-text]
80. Vessel maturation effects on tumour growth: validation of a computer model in implanted human ovarian carcinoma spheroids.
    Eur J Cancer, 41(1): 159-67. [Abstract] [Full-text]
81. Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report.
    Eur J Cancer, 41(1): 143-50. [Abstract] [Full-text]
82. Symptoms and referral of women with epithelial ovarian tumors.
    Int J Gynaecol Obstet, 88(1): 31-7. [Abstract] [Full-text]
83. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines.
    Cancer Chemother Pharmacol, 55(3): 277-85. [Abstract] [Full-text]
84. Uptake of the anthracycline pirarubicin into mouse M5076 ovarian sarcoma cells via a sodium-dependent nucleoside transport system.
    Cancer Chemother Pharmacol, 55(3): 222-30. [Abstract] [Full-text]
85. Ovarian cancer in Europe: Cross-sectional trends in incidence and mortality in 28 countries, 1953-2000.
    Int J Cancer, 113(6): 977-90. [Abstract] [Full-text]
86. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity.
    Clin Cancer Res, 10(24): 8697-703. [Abstract] [Full-text]
87. Differences in prognostic molecular markers between women over and under 45 years of age with advanced ovarian cancer.
    Clin Cancer Res, 10(24): 8538-43. [Abstract] [Full-text]
88. Transcription factor AP-2gamma is a developmentally regulated marker of testicular carcinoma in situ and germ cell tumors.
    Clin Cancer Res, 10(24): 8521-30. [Abstract] [Full-text]
89. Cell cycle genes in ovarian cancer: steps toward earlier diagnosis and novel therapies.
    Clin Cancer Res, 10(24): 8132-41. [Abstract] [Full-text]
90. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.
    J Clin Oncol, 23(1): 127-32. [Abstract] [Full-text]
91. Risk of benign gynecologic tumors in relation to prenatal diethylstilbestrol exposure.
    Obstet Gynecol, 105(1): 167-73. [Abstract] [Full-text]
92. Inter-patient variation in efficacy of five oncolytic adenovirus candidates for ovarian cancer therapy.
    J Gene Med, 6(12): 1333-42. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.